source
- Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challengesAcquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
- Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trialSellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…